ArticleAnnals of the rheumatic diseases2002
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype.
Article in Annals of the rheumatic diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Multicenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti-Ro/La Antibody Detection in Primary Sjögren's Syndrome.Journal of immunology research · 2026Article
- Analytical and clinical comparison of four SLE-associated autoantibodies in different autoimmune diseases.Scientific reports · 2025Article
- Retrospective cohort study of coincident autoimmunity in dermatomyositis.Skin health and disease · 2025Article
- Article
- Antinuclear antibody (ANA) positivity pattern by line immunoassay in a hospital from eastern India: Update from a laboratory perspective.Journal of family medicine and primary care · 2024Article
- Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study.Journal of clinical laboratory analysis · 2021Article
- Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.The Korean journal of internal medicine · 2021Article
- Sicca syndrome in the same family - the importance of anti-Ro60, anti-Ro52 and anti-La antibody profiling in Sjögren's syndrome.Reumatologia · 2021Article
- Ultrasonography predicts the results of labial salivary gland biopsy in patients with suspected Sjögren's syndrome: a matrix risk model.Therapeutic advances in musculoskeletal disease · 2021Article
- Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.Arthritis research & therapy · 2020Article
- Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.Frontiers in immunology · 2019Observational
- Article
- The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome.Annals of the rheumatic diseases · 2015Article
- [Systemic lupus and kidney disease: contribution of anti-SSA].The Pan African medical journal · 2015Article
- Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren's syndrome.Arthritis research & therapy · 2014Article
- Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus.Experimental and therapeutic medicine · 2013Article
- Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus.TheScientificWorldJournal · 2013Article
- Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.Arthritis research & therapy · 2012Article
- The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome.Rheumatology international · 2012Article
- Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.Journal of autoimmune diseases · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population.
methodsA total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cells. Serum samples positive for ANAs were analysed by immunodiffusion and line immunoassay with recombinant SSA-Ro52, natural SSA-Ro60, and recombinant SSB.
resultsAmong ANA positive patients in whom clinical information was available, 181 consecutive patients with anti-SSA and/or anti-SSB antibodies were identified, Disease associations were systemic lupus erythematosus (SLE) (45.3%), primary Sjögren's syndrome (pSS) (14.4%), scleroderma (8.8%), RA (7.7%), cutaneous lupus (7.7%), and dermatomyositis (2.2%). The ratio of diagnoses differed according to the anti-SSA/anti-SSB serotype. Scleroderma and dermatomyositis were enriched among mono-Ro52 reactive serum samples (34.2% and 10.5% respectively). Single reactivity towards Ro60 or anti-Ro60 with anti-Ro52 predisposed for SLE (80.0% and 52.2% respectively). Triple reactivity towards Ro52, Ro60, and SSB was primarily linked with SLE (55.8%) followed by pSS (20.9%). Anti-SSA on immunodiffusion increased the chance for SLE (62.8%), whereas isolated anti-SSB reactivity on immunodiffusion was less indicative for SLE (14.3%) and predisposed more for cutaneous lupus (23.8%) and pSS (33.3%).
conclusionThe diagnostic range associated with anti-SSA or anti-SSB reactivity differs significantly according to the detailed serotype defined by line immunoassay and immunodiffusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.